ApoA-1 Milano
|
WikiDoc Resources for ApoA-1 Milano |
|
Articles |
|---|
|
Most recent articles on ApoA-1 Milano Most cited articles on ApoA-1 Milano |
|
Media |
|
Powerpoint slides on ApoA-1 Milano |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on ApoA-1 Milano at Clinical Trials.gov Trial results on ApoA-1 Milano Clinical Trials on ApoA-1 Milano at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on ApoA-1 Milano NICE Guidance on ApoA-1 Milano
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on ApoA-1 Milano Discussion groups on ApoA-1 Milano Patient Handouts on ApoA-1 Milano Directions to Hospitals Treating ApoA-1 Milano Risk calculators and risk factors for ApoA-1 Milano
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for ApoA-1 Milano |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
A naturally-occurring mutated strain of the apoA-1 protein found in human HDL. First identified by Cesare Sirtori in Milan, it has been shown to significantly reduce arterial plaque.
Discovered by accident, the mutation was found to be present in about 3.5% of a tiny village called Limone sul Garda in northern Italy. It has been traced to a mutation in a single man living in the village in the 1700s.
Due to its enormous apparent efficacy, some have speculated that development of synthetic apoA-1 Milano may be a key factor in eradicating coronary heart disease.
No drugs are currently commercially available based on apoA-1 Milano. Rights to apoA-1 Milano were acquired in 2003 by Pfizer. Clinically known as ETC-216, Pfizer has not moved trials forward, posssibley because the drug must be administred intravenously, thus limiting its application as compared to oral medications[1].
References
- ↑ Sue Hughes, ERASE: New HDL Mimetic Shows Promise, Heartwire